Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 559
Year : 2010  |  Volume : 2  |  Issue : 9  |  Page : 403-408

Whole blood viscosity assessment issues V: Prevalence in hypercreatinaemia, hyperglycaemia and hyperlipidaemia

Western Pathology Cluster NSW Health, South West Pathology Service; 590 Smollett Street Albury, Australia

Correspondence Address:
Ezekiel Uba Nwose
Western Pathology Cluster NSW Health, South West Pathology Service; 590 Smollett Street Albury, NSW 2640
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Background : Diabetes and kidney failure are chronic diseases that are associated with cardiovascular complications, while dyslipidaemia is a strong risk factor. Hyperviscosity is believed to be associated and managed with antiplatelet, but not routinely assessed. Aims : This work investigates the prevalence of hyperviscosity in diabetes, dyslipidaemia and renal failure with a view to determine the proportion of patients who may not require antiplatelet therapy. Materials and Methods : Archived clinical pathology data for the period of 1999 to 2008 were utilized. 50,162-cases concomitantly tested for blood sugar, creatinine and lipid profile, as well as haematocrit and total proteins in five alternate years were extracted. The prevalence of different viscosity ranges associated with positive results was evaluated. Results : Hyperviscosity is about 4% prevalent in hyperglycemia and hyperlipidaemia, less in hypercreatinaemia. Hypoviscosity has statistically significantly the least <2.5% prevalent, while normoviscosity is most prevalent. Reverse analyses affirm that higher levels of hyperglycemia and hyperlipidaemia are statistically significant more associated with fourth compared to first quartile viscosity (p < 0.01). Conclusion : Previous report demonstrated that hypoviscosity is synonymous to high international normalized ratio where anticoagulant/antiplatelet is not recommended. This study demonstrates that up to 97.5% of cases investigated for chronic diseases could benefit from antiplatelet medication. This report corroborates with previous reports that hyperviscosity may not be very frequent. However, the level of stasis associated with laboratory evidence-based chronic disease affirms that the subclinical vasculopathy should be managed, and laboratory monitoring will provide clinical evidence base.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded238    
    Comments [Add]    

Recommend this journal